Trial Profile
A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms TITAN
- Sponsors Ablynx
- 14 Dec 2021 Results from TITAN, HERCULES and other studies, comparing patient-centered outcomes from Germany and Austria, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 18 Feb 2021 Data from this study and HERCULES were used for cost-effective analysis of caplacizumab for immune thrombotic thrombocytopenic purpura, published in the Blood.
- 04 Dec 2018 Results analysing integrated efficacy from the individual Phase II (TITAN) and III(HERCULES) studies with Caplacizumab in patients with Acquired Thrombotic Thrombocytopenic Purpura presented at the 60th Annual Meeting and Exposition of the American Society of Hematology